This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

ESMO 2018

European Society for Medical Oncology Congress 2018

This annual meeting provides a great opportunity for education and exchange in oncology. Boehringer Ingelheim will be hosting a symposium and several publications related to our products will be presented, highlighting our advances in the treatment of cancer.

Booth #248
1 Symposium
4 Publications
19th–23rd October 2018
Meese Munich, Munich, Germany
Symposium: Treating lung cancer in a rapidly evolving landscape
symposium_cal
21 October 2018
symposium_cal
13:00pm - 14:30pm
symposium_cal
Hall B3, Room 20

At this symposium, an international faculty of experts will discuss

treatment sequencing in EGFR mutation–positive NSCLC, the efficacy of EGFR TKIs in patients with uncommon mutations, and treatment considerations for second-line and beyond in non-mutated, non-squamous NSCLC.

James Yang, MD, PhD

James Yang, MD, PhD

National Taiwan University
Taipei, Taiwan

Panel discussion: treatment considerations for non-mutated, non-squamous NSCLC

Maximilian Hochmair, MD

Maximilian Hochmair, MD

Otto Wagner Hospital
Vienna, Austria

Sequencing in EGFR-mutated NSCLC: does order matter?

Edward S. Kim, MD

Edward S. Kim, MD

Levine Cancer Institute

North Carolina, United States

Efficacy of EGFR TKIs in patients with uncommon mutations

Sanjay Popat, BSc, MBBS, FRCP, PhD

Sanjay Popat, BSc, MBBS, FRCP, PhD

Royal Marsden Hospital

London, UK

Treating second-line and beyond in non-mutated, non-squamous NSCLC: now and tomorrow

Publications
Filter by:
Presentation Type
  • Oral Presentation
  • Poster Presentation
  • e-Presentation
Tumour Type

Visit us again after the congress to download the publications.

Saturday 20th October 2018
Afatinib* versus erlotinib as second-line treatment of patients with advanced lung squamous cell carcinoma: final analysis of the global phase III LUX-Lung 8 trial
20th October 2018
12:30-13:30
Hall A3
Presenter(s): Glenwood Goss
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: 1442P
Efficacy of Afatinib in the clinical practice - First results of the GIDEON trial: a prospective non-interventional study (NIS) in EGFR mutated NSCLC in Germany
20th October 2018
12:30-13:30
Hall A3
Presenter(s): Wolfgang Brueckl
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: 1449P
Phase IV, open-label, multicentre trial of afatinib in patients (pts) aged ≥70 yrs with NSCLC harbouring common (Del19/L858R) EGFR mutations: preliminary results
20th October 2018
12:30-13:30
Hall A3
Presenter(s): Karen Reckamp
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: 1456P
Phase I study of BI 754111 (anti-LAG-3) plus BI 754091 (anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic colorectal cancer (mCRC), anti-PD-(L)1-pretreated non-small-cell lung cancer (NSCLC) and other solid tumors
20th October 2018
12:30-13:30
Hall A3
Presenter(s): Melissa Johnson
Poster Presentation
Tumour Type(s): Solid tumours, CRC, NSCLC
Presentation Number: 1243TiP
There are no publications which meet your criteria on this date

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

 

© 2018 Boehringer Ingelheim International GmbH. All rights reserved.

 

 Last updated: September 2018